Graftoss is a company formed by WaikatoLink Limited, the technology transfer office of the University of Waikato in Hamilton, New Zealand. The company’s technology is protected by Patent.
Graftoss’s bone matrix technology has applications as a xenograft material for human and veterinary grafting, including spinal fusion, hand and foot surgery, simple and complex fractures repair, joint reconstruction and dental implants, and as an antibiotic impregnated graft material for application in conditions such as osteomyelitis.
In late 2007 Graftoss was successful in attracting investment from Venture Capital Firm Endeavour Capital which has allowed the company to continue developing this leading edge technology. We are actively seeking partners in the development and commercialisation of this technology.
To make an enquiry please click here.
Graftoss Limited is a medical device company which is developing a bone implant sourced from bovine bone for use by surgeons and veterinarians.
The processed bone has its indigenous organic compounds removed, and is then reinforced with an organic biocompatible matrix, providing mechanical strength and aiding in bone regeneration.
Graftoss’s bone matrix technology has applications as a xenograft material for human and veterinary grafting, including spinal fusion, hand and foot surgery, simple and complex fractures repair, joint reconstruction and dental implants, and as an antibiotic impregnated graft material for application in conditions such as osteomyelitis.
Patent applications have been filed. Graftoss’s strategy is to develop a portfolio of patents for bone graft and bone replacement technologies through acquisition, partnering or in-licensing.
This technology is at early stage proof of concept. Graftoss is seeking early access relationships and research and development partners for the continued development of this technology.
To download a company profile, please click here.